Please assess the completion status of the following clinical trial:

Trial Title: The PK/PD Study of SHR7280 Tablets in Healthy Subjects.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 11.0

Eligibility Criteria:
Inclusion Criteria:~PART 1:~1. Healthy males , aged 18-65;~2. BMI 18 \~ 30 kg/m2;~3. Subjects in general good health. No clinically significant findings in Physical examination and auxiliary examination.~PART 2:~1. premenopausal females, aged 18-45;~2. BMI 18 \~ 30 kg/m2;~3. Subjects in general good health. No clinically significant findings in Physical examination and auxiliary examination.~Exclusion Criteria:~PART 1~1. Testosterone (T) \< 12 nmol/L;~2. ALT or AST or total bilirubin exceeds the upper limit of normal;~3. Those with positive nicotine test and alcohol breath test before administration, and those with positive drug screening before administration;~4. Use of any medication within 1 month before administration; or use of medication that does not exceed 5 half-lives, whichever is longer;~5. Subjects with chronic diseases or serious diseases that affect drug absorption, distribution, metabolism and excretion;~6. Blood donation or donation of blood components within 1 month before screening, or loss of blood equivalent to at least 200 mL, or transfusion within 2 months;~7. Use of GnRH agonists and GnRH antagonists within 6 months before screening and use of any androgens and antiandrogens within 5 half-lives before screening;~8. Subjects with severe infection, severe trauma or major surgery within 6 months before screening;~9. Positive results of infectious disease screening .~10. Allergic constitution or allergy to two or more kinds of food and drugs, including known history of allergy to the study drug or any component of the study drug.~PART 2:~1. Pregnant or breast feeding;~2. FSH≥25U/L;~3. Positive serum pregnancy test (serum β-HCG test) result;~4. Abnormal uterine bleeding within 3 months prior to screening~5. ALT or AST or total bilirubin exceeds the upper limit of normal;~6. Those with positive nicotine test and alcohol breath test before administration, and those with positive drug screening before administration;~7. Use of any medication within 1 month before administration; or use of medication that does not exceed 5 half-lives, whichever is longer;~8. Subjects with chronic diseases or serious diseases that affect drug absorption, distribution, metabolism and excretion;~9. Blood donation or donation of blood components within 1 month before screening, or loss of blood equivalent to at least 200 mL, or transfusion within 2 months;~10. GnRH agonist use 6 months prior to Screening and GnRH antagonist or any sex hormone use 2 months prior to Screening.~11. Subjects with severe infection, severe trauma or major surgery within 6 months before screening~12. Positive results of infectious disease screening .~13. Allergic constitution or allergy to two or more kinds of food and drugs, including known history of allergy to the study drug or any component of the study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- SHR7280 dose 1(male) (Type: EXPERIMENTAL): oral administration for 14 days,Phase I(PART 1)
- SHR7280 dose 2(male) (Type: EXPERIMENTAL): oral administration for 14 days,Phase I(PART 1)
- SHR7280 dose 3(male) (Type: EXPERIMENTAL): oral administration for 14 days,Phase I(PART 1)
- SHR7280 dose 4(male) (Type: EXPERIMENTAL): oral administration for 14 days,Phase I(PART 1)
- SHR7280 dose 5(male) (Type: EXPERIMENTAL): oral administration for 14 days,Phase I(PART 1)
- SHR7280 dose 1(female) (Type: EXPERIMENTAL): oral administration for 21 days,Phase I(PART 2)
- SHR7280 dose 2(female) (Type: EXPERIMENTAL): oral administration for 21 days,Phase I(PART 2)
- SHR7280 dose 3(female) (Type: EXPERIMENTAL): oral administration for 21 days,Phase I(PART 2)
- SHR7280 dose 4(female) (Type: EXPERIMENTAL): oral administration for 21 days,Phase I(PART 2)
- SHR7280 dose 6(male) (Type: EXPERIMENTAL): oral administration for 14 days,Phase I(PART 1)
- SHR7280 dose 7(male) (Type: EXPERIMENTAL): oral administration for 14 days,Phase I(PART 1)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete